Resolute zotarolimus-eluting stents had similar risks of target-vessel revascularization (RR 1.06; 95% CI 0.90-1.24; P=0.50) and stent thrombosis compared with everolimus-eluting stents.
Meta-Analysis (n=9,899)
Does the Resolute zotarolimus-eluting stent improve efficacy or safety outcomes compared to the everolimus-eluting stent in patients undergoing percutaneous coronary intervention?
Resolute zotarolimus-eluting stents and everolimus-eluting stents demonstrate comparable safety and efficacy profiles in patients undergoing percutaneous coronary intervention.
Effect estimate: RR 1.06 (95% CI 0.90-1.24)
p-value: p=0.50
BACKGROUND: Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and the risk of stent thrombosis between the Resolute zotarolimus-eluting stent (R-ZES) and the everolimus-eluting stent (EES). The aim of this study was to evaluate the safety and efficacy of the R-ZES compared with EES in patients undergoing percutaneous coronary intervention. METHODS AND RESULTS: A systematic literature search of electronic resources was performed using specific search terms until September 2014. Random-effects meta-analysis was performed comparing clinical outcomes between patients treated with R-ZES and EES up to maximum available follow-up. The primary efficacy end point was target-vessel revascularization. The primary safety end point was definite or probable stent thrombosis. Secondary safety end points were cardiac death and target-vessel myocardial infarction. Five trials were identified, including a total of 9899 patients. Compared with EES, R-ZES had similar risks of target-vessel revascularization (risk ratio RR, 1.06; 95% confidence interval CI, 0.90-1.24; P=0.50), definite or probable stent thrombosis (RR, 1.26; 95% CI, 0.86-1.85; P=0.24), cardiac death (RR, 1.01; 95% CI, 0.79-1.30; P=0.91), and target-vessel myocardial infarction (RR, 1.10; 95% CI, 0.89-1.36; P=0.39). Moreover, R-ZES and EES had similar risks of late definite or probable very late stent thrombosis (RR, 1.06; 95% CI, 0.53-2.11; P=0.87). No evidence of significant heterogeneity was observed across trials. CONCLUSIONS: R-ZES and EES provide similar safety and efficacy among patients undergoing percutaneous coronary intervention.
Piccolo et al. (Wed,) conducted a meta-analysis in percutaneous coronary intervention (n=9,899). Resolute zotarolimus-eluting stent (R-ZES) vs. everolimus-eluting stent (EES) was evaluated on target-vessel revascularization (RR 1.06, 95% CI 0.90-1.24, p=0.50). Resolute zotarolimus-eluting stents had similar risks of target-vessel revascularization (RR 1.06; 95% CI 0.90-1.24; P=0.50) and stent thrombosis compared with everolimus-eluting stents.